Institute for Community Medicine, Ernst-Moritz-Arndt-University Greifswald, Walther-Rathenau-Str 48, 17487 Greifswald, Germany.
Int J Cardiol. 2013 Sep 10;167(6):2786-91. doi: 10.1016/j.ijcard.2012.07.011. Epub 2012 Aug 9.
BACKGROUND: Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular disease in the general population and in patients with chronic kidney disease. The objective of this study was to investigate the association of estimated glomerular filtration rate (eGFR) with left ventricular mass index (LVMI), LVH and left ventricular geometry. A question of clinical relevance is whether estimated glomerular filtration rate based on cystatin C (eGFRcystatinC) is a better marker for cardiovascular risk than estimated glomerular filtration rate based on creatinine (eGFRcreatinine). METHODS: The study sample included 2830 individuals from the population-based Study of Health in Pomerania (SHIP). LVH was defined as echocardiographic LVMI >48 g/m(2.7) in men and >44 g/m(2.7) in women. Kidney function, as assessed by eGFR, was determined from established equations: the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and a cystatin-based multivariable equation. RESULTS: We found an inverse association between eGFR and LVMI. This association was stronger in models with eGFRcystatinC than in models with eGFRcreatinine. Subjects with moderately-to-severely decreased kidney function (defined as eGFR 15-<60 mL/min per 1.73 m(2)) had higher odds for abnormal geometric patterns of the left ventricle than subjects with normal eGFR when eGFRcystatinC was used. CONCLUSIONS: The findings suggest that eGFRcystatinC is superior to eGFRcreatinine for assessing the risk of cardiovascular disease.
背景:左心室肥厚(LVH)是普通人群和慢性肾脏病患者心血管疾病的独立预测因子。本研究的目的是探讨估算肾小球滤过率(eGFR)与左心室质量指数(LVMI)、LVH 和左心室几何结构的关系。一个具有临床相关性的问题是,基于半胱氨酸蛋白酶抑制剂 C(eGFRcystatinC)的估算肾小球滤过率是否比基于肌酐(eGFRcreatinine)的估算肾小球滤过率更能作为心血管风险的标志物。
方法:本研究样本包括来自基于人群的波罗的海健康研究(SHIP)的 2830 名个体。LVH 定义为超声心动图左心室质量指数(LVMI)男性>48 g/m(2.7),女性>44 g/m(2.7)。通过已建立的方程评估肾功能,即基于肌酐的慢性肾脏病流行病学合作(CKD-EPI)方程和基于半胱氨酸蛋白酶抑制剂的多变量方程。
结果:我们发现 eGFR 与 LVMI 呈负相关。这种相关性在 eGFRcystatinC 模型中比在 eGFRcreatinine 模型中更强。当使用 eGFRcystatinC 时,肾功能中度至重度降低(定义为 eGFR 为 15-<60 mL/min per 1.73 m(2))的患者发生左心室异常几何形态的几率高于 eGFR 正常的患者。
结论:这些发现表明,eGFRcystatinC 比 eGFRcreatinine 更能评估心血管疾病的风险。
Pol Merkur Lekarski. 2008-10
Int J Clin Pract. 2011-4
Gut Microbes. 2018-5-31
Nephrol Dial Transplant. 2015-8
Curr Hypertens Rep. 2015-9